Pathophysiology of bone metastases

Cancer Biology and Therapy

Volumn 5, Issue 9, 2006, Pages 1078-1081

  Berenson, James R ^a,c   Rajdev, Lakshmi ^b   Broder, Michael ^c  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

Bone; Metastasis; Osteoblasts; Osteoclasts; Pathophysiology

Indexed keywords

BONE DERIVED GROWTH FACTOR; COLONY STIMULATING FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 6; LYMPHOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOMATOMEDIN C;

BONE CELL; BONE MATRIX; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; BONE STRUCTURE; CELL DAMAGE; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CORTICAL BONE; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SIGNAL TRANSDUCTION;

EID: 33751116804     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.9.3306     Document Type: Review

References (18)

1. Hage WD, Aboulafia AJ, Aboulafia DM. Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthop Clin North Am 2000; 31:515-28, vii.
2. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005; 12:549-83.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:1588-94.
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-76.
5. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0. IARCPress, Lyon, 2004.
6. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, Mateos MV, Palomera L, Fernandez-Calvo J, Marti JM, Giraldo P, Carbonell F, Callis M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J, Programa para el Estudio de la Terapeutica en Hemopatia Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106:3755-9.
7. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082-90.
8. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16:593-602.
9. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9:14-27.
10. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-smallcell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613-21.
11. Karsenty G. The complexities of skeletal biology. Nature 2003; 423:316-8.
12. Price JS, Oyajobi BO, Russell RGG. The cell biology of bone growth. In Waterlow JC, Schürch B, eds. Causes and Mechanisms of Linear Growth Retardation. Proceedings of an International Dietary Energy Consultancy Group Workshop held in London, UK. January 15-8, 1993.
13. Nather A, Ong HJC, Aziz Z. Structure of bone. In: Bone Grafts and Bone Substitutes: Basic Science and Clinical Applications. World Scientific Publishing Co. 2005.
14. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142:5050-55.
15. Hofbauer LC, Heufelder AE. Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000; 85:2355-63.
16. Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000; 106:1203-4.
17. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292:490-5.
18. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-93.